PE20060333A1 - ALKINE COMPOUNDS WITH ANTAGONIST ACTION ON MCH AND COMPOSITIONS CONTAINING THESE COMPOUNDS - Google Patents

ALKINE COMPOUNDS WITH ANTAGONIST ACTION ON MCH AND COMPOSITIONS CONTAINING THESE COMPOUNDS

Info

Publication number
PE20060333A1
PE20060333A1 PE2005000400A PE2005000400A PE20060333A1 PE 20060333 A1 PE20060333 A1 PE 20060333A1 PE 2005000400 A PE2005000400 A PE 2005000400A PE 2005000400 A PE2005000400 A PE 2005000400A PE 20060333 A1 PE20060333 A1 PE 20060333A1
Authority
PE
Peru
Prior art keywords
compounds
alkyl
mch
ethinyl
pyridin
Prior art date
Application number
PE2005000400A
Other languages
Spanish (es)
Inventor
Dirk Stenkamp
Stephan Georg Mueller
Thorsten Lehmann-Lintz
Klaus Rudolf
Leo Thomas
Ralf R H Lotz
Marcus Schindler
Gerald Juergen Roth
Philipp Lustenberger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20060333A1 publication Critical patent/PE20060333A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

REFERIDA A UN COMPUESTO ALQUINICO DE FORMULA I, DONDE R1 ES ALQUENILO C3-C6, ALQUINILO C3-C6, ENTRE OTROS; R2 ES H, ALQUILO C1-C8, CICLOALQUILO C3-C7, ENTRE OTROS; X ES ALQUILENO C1-C4, ENTRE OTROS; W Y Z SON UN ENLACE SENCILLO O UN PUENTE ALQUILENO C1-C2, ENTRE OTROS; Y Y A SON FENILO, PIRIDINILO, PIRIMIDINILO, ENTRE OTROS; B ES ALQUILO C1-C6, ALQUENILO C1-C6, ALQUINILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3S,4R)-1-(2-{4-[5-(4-CLOROFENIL)-PIRIDIN-2-IL-ETINIL]-2-METIL-FENOXI}-ETIL)-4-TRIFLUOROMETIL-PIPERIDIN-3,4-DIOL, (S)-3-[(2-{4-[5-(4-CLOROFENIL)-PIRIDIN-2-IL-ETINIL]-2-METIL-FENOXI}-ETIL)-CICLOPROPILMETIL-AMINO]-PROPANO-1,2-DIOL, (R)-3-[(2-{4-[5-(4-CLOROFENIL)-PIRIDIN-2-IL-ETINIL]-2-METIL-FENOXI}-ETIL)-CICLOPROPILMETIL-AMINO]-PROPANO-1,2-DIOL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION QUE CONTIENE DICHOS COMPUESTOS, LOS CUALES SON ANTAGONISTAS DEL RECEPTOR DE LA HORMONA CONCENTRADORA DE MELANINA (MCH) Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS Y/O TRASTORNOS ALIMENTARIOS, EN PARTICULAR DE LA ADIPOSIDAD Y DIABETESREFERRED TO AN ALKINE COMPOUND OF FORMULA I, WHERE R1 IS C3-C6 ALKENYL, C3-C6 ALKYNYL, AMONG OTHERS; R2 IS H, C1-C8 ALKYL, C3-C7 CYCLOALKYL, AMONG OTHERS; X IS C1-C4 ALKYLENE, AMONG OTHERS; W AND Z ARE A SIMPLE LINK OR A C1-C2 ALKYLENE BRIDGE, AMONG OTHERS; AND AND A ARE PHENYL, PYRIDINYL, PYRIMIDINYL, AMONG OTHERS; B IS C1-C6 ALKYL, C1-C6 ALKYL, C1-C6 ALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (3S, 4R) -1- (2- {4- [5- (4-CHLOROPHENYL) -PYRIDIN-2-IL-ETHINYL] -2-METHYL-PHENOXY} -ETHYL) -4-TRIFLUOROMETHYL- PIPERIDIN-3,4-DIOL, (S) -3 - [(2- {4- [5- (4-CHLOROPHENYL) -PYRIDIN-2-IL-ETHINYL] -2-METHYL-PHENOXY} -ETHYL) -CYCLOPROPYLMEthyl -AMINO] -PROPANE-1,2-DIOL, (R) -3 - [(2- {4- [5- (4-CHLOROPHENYL) -PYRIDIN-2-IL-ETHINYL] -2-METHYL-PHENOXY} - ETHYL) -CYCLOPROPYLMETIL-AMINO] -PROPANE-1,2-DIOL, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND TO A COMPOSITION CONTAINING SUCH COMPOUNDS, WHICH ARE ANTAGONISTS OF THE MELANINE-CONCENTRATING HORMONE (MCH) RECEPTOR AND ARE USEFUL FOR THE TREATMENT OF METABOLICAL OR METABOLICAL DISORDERS, IN ALTHETIC DISORDERS ADIPOSITY AND DIABETES

PE2005000400A 2004-04-14 2005-04-12 ALKINE COMPOUNDS WITH ANTAGONIST ACTION ON MCH AND COMPOSITIONS CONTAINING THESE COMPOUNDS PE20060333A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004017935A DE102004017935A1 (en) 2004-04-14 2004-04-14 New alkyne compounds having MCH antagonist activity and medicaments containing these compounds

Publications (1)

Publication Number Publication Date
PE20060333A1 true PE20060333A1 (en) 2006-05-22

Family

ID=34982358

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000400A PE20060333A1 (en) 2004-04-14 2005-04-12 ALKINE COMPOUNDS WITH ANTAGONIST ACTION ON MCH AND COMPOSITIONS CONTAINING THESE COMPOUNDS

Country Status (9)

Country Link
EP (1) EP1740572A1 (en)
JP (1) JP2007532593A (en)
AR (1) AR048692A1 (en)
CA (1) CA2559021A1 (en)
DE (1) DE102004017935A1 (en)
PE (1) PE20060333A1 (en)
TW (1) TW200602025A (en)
UY (1) UY28853A1 (en)
WO (1) WO2005103031A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017930A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
WO2008022979A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
CA2671984A1 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim International Gmbh New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
DE10250708A1 (en) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017934A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
DE102004017930A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds

Also Published As

Publication number Publication date
UY28853A1 (en) 2005-11-30
EP1740572A1 (en) 2007-01-10
JP2007532593A (en) 2007-11-15
WO2005103031A1 (en) 2005-11-03
AR048692A1 (en) 2006-05-17
TW200602025A (en) 2006-01-16
CA2559021A1 (en) 2005-11-03
DE102004017935A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
PE20051091A1 (en) SUBSTITUTE N-CYCLOHEXYLIMIDAZOLINONES AND PROCEDURES FOR THEIR PREPARATION
PE20091689A1 (en) 4-AMINOCICLOHEXANE DERIVATIVES SUBSTITUTED WITH ACTIVITY ON µ AND ENT-1 RECEPTORS
GT200500379A (en) FUSIONATED DERIVATIVES OF PIRAZOL AND METHODS OF TREATMENT OF METABOLIC DISORDERS WITH THESE
ECSP077371A (en) SYNERGIC FUNGICIDE COMPOSITIONS
UY32313A (en) HERBICIDE COMPOSITIONS CONTAINING BENZOILPIRAZOL COMPOUNDS AND OTHER HERBICIDE COMPOUND
PE20060254A1 (en) NEW COMPOUNDS WITH ALKINE STRUCTURE WITH ACTION OF MCH ANTAGONISTS AND DRUGS CONTAINING THESE COMPOUNDS
AR062111A1 (en) DERIVATIVES OF BETA-D-GLUCOPIRANOSIL INDOL, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTI-DIABETIC AGENTS.
PE20060937A1 (en) SULFONYLBENZIMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 2 (CB2) AGONISTS
PE20051054A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS SECRETAGOGS OF GROWTH HORMONE
PE20060333A1 (en) ALKINE COMPOUNDS WITH ANTAGONIST ACTION ON MCH AND COMPOSITIONS CONTAINING THESE COMPOUNDS
BR0312975A (en) Crystalline form of ß2 adrenergic receptor agonist
PE20060679A1 (en) CIS-IMIDAZOLINES AS INHIBITORS OF THE INTERACTION OF THE PROTEIN MDM2 AND POLYPEPTIDES SIMILAR TO P53
AR072952A1 (en) 2-IMINO-3-METHYL-PIRROLOPIRIMIDINONA PHENYL-REPLACED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE
PE20061316A1 (en) PIRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS
PE20080252A1 (en) USE OF ARYLCARBOXYL ACID BIPHENYLAMIDES FOR THE TREATMENT OF SEEDS
PE20091925A1 (en) INDAZOLE DERIVATIVES SUBSTITUTED WITH PHENYL OR BENZODIOXINYL
PE20070136A1 (en) COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1
PE20080835A1 (en) NOVEL AMINOPYRIDINE DERIVATIVES WHICH HAVE SELECTIVE INHIBITOR ACTION ON AURORA A
AR062109A1 (en) SUBSTITUTED DERIVATIVES OF SPIROCETAL AND USE OF THE SAME AS THERAPEUTIC PHARMACOS FOR DIABETES. PHARMACEUTICAL COMPOSITIONS.
PE20110341A1 (en) HETEROCYCLIC COMPOUNDS THAT MODULATE THE ACTIVITY OF STEROIL-CoA-DESATURASE
PE20080859A1 (en) 2-CHLORO-5- [3,6-DIHYDRO-3-METHYL-2,6-DIOXO-4- (TRIFLUORomethyl) -1- (2H) -PYRIMIDINYL] -4-FLUOR-N - [[METHYL ( 1-METHYLETHYL) AMINO] SULFONIL] BENZAMIDE
PE20091425A1 (en) AMINOTIAZOLE DERIVATIVES
AR056103A1 (en) COMPOUNDS OF (PIRAN-PIPERIDINIL) BENZIMIDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, PREPARATION PROCESS AND USES IN THE TREATMENT OF AFFECTIONS MEDIATED BY AGONISTS OF MUSCARINIC RECEIVER M1
PE20060554A1 (en) SALICILTIAZOLES SUBSTITUTED WITH DIPHENYLAMINE OR DERIVATIVES OF DIPHENYLAMINE AS INHIBITORS OF PHOSPHOTHYROSINE PHOSPHATASE 1B AND PROCEDURES FOR THEIR PREPARATION
PE20050460A1 (en) HETEROCYCLIC COMPOUNDS AS ANTAGONISTS CaSR (CALCIUM SENSITIVE RECEPTOR)

Legal Events

Date Code Title Description
FC Refusal